As the founder and managing director of enlightenbio I was leading business strategy, championing market vision, and managing all client efforts and day-to-day activities.Providing specialized strategic consultancy and advice to life science research, diagnostics, omics', and genetics startup companies to help them deliver exceptional new products and services, define company and product strategy, and reach funding goals

Evaluated and judged panel and solo proposals and submissions for inclusion at SXSW.

Providing products and services built upon the vast amount of information provided in the scientific literature and the World Wide Web. Providing strategic and tactical guidance for product development, introduction, and product promotion. Manage and develop go-to-market plans including campaigns and social programs.

Managed strategy for the different generations of the DNAnexus product (DNAnexus Classic and new DNAnexus platform) as well as SRA powered by DNAnexus (sra.dnanexus.com). Provided strategic and tactical guidance for product development, introduction, and promotion. Managed and developed marketing plans, budgets, marketing collateral, campaigns, and social programs.

IPA (Ingenuity’s flagship product) product owner, responsible for short- and long-term product roadmap, product-life cycle, development and implementation of IPA-Tox (first of its kind molecular toxicology solution within a pathways analysis tool), customer voice, marketing and field-team enablement.

Responsible for the generation and automation of high-throughput expression data, the development of the multi-disciplinary (array production, informatics, and toxicology group) DrugMatrix project. Developed, managed and led a team of 14 direct reports and 4 matrix reports driving the database development and the scientific messaging of Iconix’s flagship product DrugMatrix. Coordinated/managed all efforts of individual customer projects / collaborations related to drug development and prioritization in the area of drug toxicity and pharmacology. Scientific leader (first author) of the foundation paper describing Iconix’s flagship product DrugMatrix (J. of Biotechnology, Sept. 2005).

Established two models to analyze host responsive gene expression upon infection with eitherbacteria or purified endotoxins to mimic septic shock in cell culture, as a first step towardsrevealing its molecular fingerprint.Coordinated the colon cancer team efforts for high-throughput genomic approaches for diagnostics and therapeutics.